Generic pharmaceutical manufacturer Natco has secured a compulsory licence to produce cancer drug Nexavar for the Indian market. Ranjna Mehta-Dutt and Shukadev Khuraijam report.
“The beginning is easy; what happens next is much harder”—Anonymous
Against the backdrop of an illusory Indian spring, the Indian patent office bequeathed India’s first compulsory licence to a local generic drug manufacturer: Natco Pharma. In doing so, it placed into practical circulation an untested provision—one it, apparently, considered perfect on paper. Germany’s Bayer, which had been granted the patent in question for its liver/kidney cancer drug Nexavar, has so far kept its future intention on the matter under wraps.
The decision was issued by PH Kurian on his last day in office as the controller general of patents, designs and trademarks. Having essayed many ground-breaking transformations at the patent office during his tenure, he can be said to have ‘gone out with a bang’ after seemingly opening the flood gates with this unprecedented ruling.
To continue reading, you need a subscription to WIPR. Start a subscription to WIPR for £455.
In-house feature articles, the archive and expert comment require a paid subscription. Subscribe now.
Want to give it a try? We are offering a two week free trial to the WIPR website – register and select “Free Trial” to begin access to the full WIPR archive and read the latest news, features and expert comment. Begin your free trial here.
Is your 2 week free trial about to end? Upgrade to a 12 month subscription for £455 now.
If you have already subscribed please login.
If you have any technical issues please email James Lynn on firstname.lastname@example.org.
compulsory licensing, Natco, pharmaceuticals